CSF beta‐amyloid 1–42 – what are we measuring in Alzheimer's disease?
Open Access
- 19 December 2014
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 2 (2) , 131-139
Abstract
Objective: To characterize biological and technical factors which influence cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarker levels, including the presence of apolipoprotein E (APOE) ε4 allele, AD diagnosis, Aβ‐binding proteins, sample processing, and preanalytical handling.Methods: CSF was collected from 140 subjects with normal cognition, mild cognitive impairment, AD, and non‐AD dementia. CSF levels of beta‐amyloid 1–42 (Aβ42), total Tau (t‐Tau), and Tau phosphorylated at threonine 181 (p‐Tau181) were analyzed following the standard and modified protocols. CSF levels of apoJ, apoE, albumin, and α‐synuclein were measured in a subgroup (n = 69), and their effects on measured AD biomarker levels were also determined in vitro using human CSF samples.Results: CSF Aβ42 levels measured using the AD Neuro‐imaging Initiative (ADNI) protocol (which we call suspended Aβ42 or susAβ) were lower than total measurable CSF Aβ42 in all groups, and on average represents 57% of the latter. Logistic regression analysis showed this proportion (% susAβ) to be directly correlated with CSF Aβ42 and apoJ levels, but inversely correlated with CSF t‐Tau levels. Finally, we showed in vitro that increasing apoE and apoJ levels directly increased % susAβ.Conclusion: CSF susAβ levels are influenced by biological and technical factors, and may represent a marker of Aβ susceptible to lipoprotein‐mediated clearance. Clinical trials should include total measurable Aβ42 and susAβ to better inform outcomes.Keywords
Funding Information
- National Institutes of Health (AG 016976)
- National Institutes of Health (AG 042856)
- Viretta Brady Discovery Fund
This publication has 39 references indexed in Scilit:
- Preclinical Alzheimer's disease and its outcome: a longitudinal cohort studyThe Lancet Neurology, 2013
- CSF Presenilin-1 complexes are increased in Alzheimer’s diseaseActa Neuropathologica Communications, 2013
- CSF biomarker variability in the Alzheimer's Association quality control programAlzheimer's & Dementia, 2013
- Proficiency Testing Programs for Alzheimer’s Disease Cerebrospinal Fluid BiomarkersBiomarkers in Medicine, 2012
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's DiseasesPLOS ONE, 2008
- Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stageNeuroImage, 2008
- Amino-Truncated β-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive ImpairmentClinical Chemistry, 2005
- Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseasesNeurobiology of Aging, 2005
- Characterization of Apolipoprotein J-Alzheimer's Aβ InteractionJournal of Biological Chemistry, 1995